Fitbit, world leading brand in Wearables, and Dexcom leading company in continuous glucose monitoring have announced that they will collaborate in the development of new products that help people with diabetes to better manage their illness.
The first initiative raised within the scope of this collaboration goes through the possibility of importing the Dexcom data to the new Fitbit Smartwatch, called Fitbit ionic.
Through this option, Dexcom users on both Android and iOS devices, can see their records in their wrist both of their physical activity and their glucose levels.
"The strength of our brand and our ability to track critical health metrics continuously for a maximum of 4 days along with the leadership of the Dexcom market, they have a powerful combination that we hope will help millions of people to better manage their diabetes,"James Park, CEO of Fitbit, has highlighted in relation to this agreement.
For his part, Kevin Sayer, president of Dexcom has affirmed that "the collaboration between Dexcom and Fitbit is an important step in the provision of information for people with diabetes that is convenient and discreet", to add that "we believe that the supply ofDEXCOM CGM data on Fitbit Ionic, will have a positive effect in the way people handle their diabetes. "
The Fitbit Ionic offers a very personalized, unique experience in the current smartwatches, since it has a spo2 relative sensor, leader in the GPS industry, dynamic exercises on the device, improved heart rate of heart rate and water resistance up to 50 meters.
In addition, it has intelligent characteristics such as contactless payments, music, intelligent notifications, and a variety of popular applications available in the Fitbit App Gallery.
IONIC also has all the main features of Fitbit, as 4 days of battery, automatic activity and sleep monitoring.
In this way, Dexcom users can connect with millions of people, where they can ask questions, seek support and share successes in the management of their diabetes.
The new device is expected in early 2018;and that both companies continue to explore opportunities to work together in the development of tools and resources aimed at helping people with diabetes to manage their pathology.
